 Molecular Templates, Inc. Nasdaq: MTEM, Molecular Templates, MTEM or the Company, a clinical-stage biopharmaceutical company focused on the discovery and development of the Companys proprietary targeted biologic therapeutics, engineered toxin bodies ETBs, today announced it has secured a debt financing facility for up to 45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of 15 million upon closing, a portion of which has been used to repay the remaining indebtedness that was outstanding under the Companys prior credit facility. Two subsequent tranches totaling up to 30 million will become available to MTEM, at its option, upon the achievement of certain milestones with respect to the second tranche and, subject to lender consent and certain additional conditions with respect to the third tranche. 